Daxor Corporation Common Stock (DXR) is a publicly traded Healthcare sector company. As of May 21, 2026, DXR trades at $11.35 with a market cap of $63.81M and a P/E ratio of 0.00. DXR moved +0.00% today. Year to date, DXR is -21.38%; over the trailing twelve months it is +50.73%. Its 52-week range spans $6.55 to $14.76. Analyst consensus is buy with an average price target of $22.50. Rallies surfaces DXR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Daxor Validates BVA’s 20% Hourly Albumin Leak Detection in Heart Failure Study: Daxor’s Blood Volume Analyzer measured a median 20% per hour albumin escape rate in a heart failure cohort, while four standard clinical indices showed uniformly low scores. The data confirms BVA’s unique mechanistic specificity and positions it as the only bedside tool for direct capillary leak quantification.
| Metric | Value |
|---|---|
| Price | $11.35 |
| Market Cap | $63.81M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.03% |
| 52-Week High | $14.76 |
| 52-Week Low | $6.55 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.45M |
| Net Income | $-7.19M |
| Gross Margin | 54.89% |
2 analysts cover DXR: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $22.50.